2-(4Ј-Methylaminophenyl)benzothiazole (BTA-1) is an uncharged derivative of thioflavin-T that has high affinity for A␤ fibrils and shows very good brain entry and clearance. In this study, we asked whether BTA-1, at concentrations typical of those achieved during positron emission tomography (PET) studies, could specifically bind to amyloid deposits in the complex milieu of human brain or whether amyloid binding was overshadowed by nonspecific binding, found even in brains that did not contain amyloid deposits. We quantitatively assessed [ 
Introduction
Alzheimer's disease (AD) is defined pathologically by the characteristic deposits found in the brain (Mirra et al., 1991) , including amyloid plaques and neurofibrillary tangles (NFTs). Both the amyloid-␤ (A␤) protein found in plaques and the tau protein found in NFTs have a predominantly ␤-sheet structure (Kirschner et al., 1986) . Current evidence suggests that both A␤ and tau deposits play important roles in the pathophysiological cascade of AD (Goate et al., 1991; Mullan et al., 1992; Hardy et al., 1998; Goedert and Spillantini, 2000; Golde et al., 2000) .
A␤ deposition has become an important therapeutic target in AD research (Schenk et al., 1999; Bard et al., 2000; DeMattos et al., 2001; Olson et al., 2001) . Although promising anti-amyloid therapies are being intensely pursued, there is currently no accepted tool to directly assess their success in delaying or reversing amyloid deposition in humans. It will be critical to show that a clinical treatment effectively reduces plaque load, before positive or negative effects on clinical cognitive measures can be accurately interpreted. In addition, because the clinical effectiveness of these anti-amyloid therapies will serve as a test of the "amyloid hypothesis" of AD (Hardy and Allsop, 1991; Hardy, 1992) , it also will be critical to show that the treatments actually decrease amyloid load before we can make inferences about the validity of the amyloid hypothesis.
Our laboratory has been interested in the development of a noninvasive method for direct and quantitative assessment of amyloid deposition in living subjects (Klunk et al., 1994; Klunk, 1998) . We have reported the potential of lipophilic thioflavin-T analogs as amyloid imaging agents (Klunk et al., 2001 ) and have described a particularly promising carbon-11-labeled derivative of thioflavin-T, namely 2-(4Ј-methylaminophenyl)benzothiazole (BTA-1) (see Fig.  1 ) (Mathis et al., 2002) . BTA-1 shows very good brain entry and clearance and has been used for in vivo imaging of amyloid deposits in living presenilin-1/amyloid precursor protein transgenic mice using multiphoton microscopy (Mathis et al., 2002) . These properties justified further pursuit of BTA-1 as an in vivo human amyloidimaging agent for positron emission tomography (PET).
A critical issue in the development of a PET imaging agent is whether binding to brain tissue is dominated by the specific target (in this case, amyloid deposits) or by nonspecific, background binding. Here, we further assessed the utility of BTA-1 for in vivo PET imaging studies by quantitatively assessing its binding to homogenates of postmortem brain from nine AD subjects, eight controls, and six subjects with non-AD dementia (NAD). We found that BTA-1 binding was much higher in amyloidcontaining areas of AD brain tissue, and most of the binding appeared to be specific. In addition, the K i of various BTA analogs for inhibition of [ 3 H]BTA-1 binding to AD brain homogenates was very similar to their K i for inhibition of [
3 H]BTA-1 binding to synthetic A␤ fibrils. These data suggest that the binding of BTA-1 to AD brain is dominated by specific interaction with amyloid deposits and strengthen the case for use of BTA-1 as an in vivo imaging agent for AD diagnosis and treatment assessment.
Materials and Methods
Chemicals. Chemicals were obtained from Sigma (St. Louis, MO) unless noted otherwise. Tritium-labeled and unlabeled BTA-1, and BTA-1 derivatives, were synthesized and characterized as described previously (Klunk et al., 2001; Mathis et al., 2002) .
Postmortem tissue. Autopsy tissue was obtained from the University of Pittsburgh Alzheimer Disease Research Center Brain Bank. Clinical and postmortem diagnoses were made by standardized procedures as described previously in detail (Lopez et al., 2000) . Clinical characteristics are shown in Table 1 .
All nine AD brains represented fairly advanced stages of pathology as is typical of postmortem tissue. The eight control and six NAD brains were selected for having no significant evidence of neuritic plaques or cerebrovascular amyloid. In addition, there were no NFTs in the frontal cortex of any control or NAD case. Samples of medial-frontal cortex gray matter, medial-frontal cortex white matter, entorhinal cortex (EC), or cerebellum were dissected at autopsy from 1-cm-thick coronal slices and frozen at Ϫ80°C. The tissue was homogenized with a Polytron tissue homogenizer (PT 10/35; Brinkman Instruments, Westbury, NY) at room temperature for 30 sec at setting 6 in PBS (137 mM NaCl, 3 mM KCl, 10 mM sodium phosphate, pH 7.0) at a concentration of 10 mg of brain per milliliter. The homogenates were aliquoted and frozen at Ϫ80°C until used for binding assays within 2 months. No significant changes in binding characteristics were observed in samples assayed repeatedly over this time period.
Neuroreceptor screening. Binding assays for receptors and transporters were performed as described previously using the resources of the National Institute of Mental Health Psychoactive Drug Screening Program (Roth et al., 2000 (Roth et al., , 2001 .
Binding studies. A␤(1-40) fibrils were prepared, and K i determinations were performed as described previously (Klunk et al., 2001) using [N-methyl- 3 H]BTA-1 ([ 3 H]BTA-1; 61 Ci/mmol) as the radioligand (Mathis et al., 2002) . Binding to brain homogenates for determination of K i and K d was performed with slight modifications. Briefly, 10 mg/ml frozen brain aliquots were thawed and diluted 10-fold in PBS to 1 mg/ml. Unlabeled test compounds were dissolved in DMSO at 400 M (to yield Ͻ1% DMSO in the final assay). The appropriate concentrations of unlabeled test compounds were combined with [
3 H]BTA-1 (ϳ1.2 nM) in a volume of 900 l of PBS, pH 7.0. The assay was begun by addition of 100 l of the 1 mg/ml brain homogenate to achieve a final concentration of 100 g tissue per milliliter. After incubation for 60 min at room temperature, the binding mixture was filtered through a Whatman GF/B glass filter via a Brandel M-24R cell harvester (Gaithersburg, MD) and rapidly washed five times with 3 ml PBS. The filters were counted in Cytoscint-ES after thorough vortexing and sitting overnight. Complete (100%) inhibition of specific binding was defined as the number of counts displaced by 3 M unlabeled BTA-1. All assays were performed at least in triplicate. For determination of K i values, inhibition curves were fit (using the RS/1 statistical package, version 6.1; Brooks Automation, Chelmsford, MA) to the following equation, which is derived from the Hill equation (Bennett and Yamamura, 1985) : Tissue staining. Postmortem tissue from three of the autopsyconfirmed AD cases used for the binding study was obtained through the University of Pittsburgh Alzheimer Disease Research Center. Samples of medial-frontal cortex, entorhinal cortex, or cerebellum were dissected from 1-cm-thick coronal slices and placed into 10% buffered formalin (7 d). Paraffin blocks were prepared by sequential dehydration in graded alcohol and vacuum infiltrated in paraffin before embedding and serial sectioning at a thickness of 8 m. Tissue was processed for staining, and quenching of autofluorescence was accomplished according to previously described methods (Styren et al., 2000) . Quenched tissue sections were taken from PBS into a solution of 100 nM BTA-1 in PBS, pH 7.0, for 45 min. The sections were then dipped into water for ϳ5 sec before coverslipping with Fluoromount-G (Electron Microscopy Sciences, Fort Washington, PA). Fluorescent sections were viewed using an Olympus Vanox AH-RFL-LB fluorescence microscope using a UV filter set: Ufilter (excites 360 -370 nm, dichroic mirror DM400, 420 nm long-pass filter). X-34 staining was performed according to previously described methods (Styren et al., 2000) . X-34-stained tissue sections were optimally viewed with a violet filter set: V-filter (excites Ͻ460 nm, DM455 mirror, 455 nm long-pass filter).
Results
Paraffin sections (8 m) from the frontal and entorhinal cortex of AD brain were stained with 100 nM BTA-1 (Figs. 1 , 2 ). Like the parent compound, thioflavin-T (Klunk et al., 2001) , BTA-1 stained plaques, cerebrovascular amyloid, and NFTs at these relatively high concentrations. BTA-1 appeared to stain plaques and cerebrovascular amyloid more intensely than it stained NFTs. Very little background staining was observed. Most of the background fluorescence seen in Figure 2 was caused by residual lipofuscin autofluorescence (distinguished by the fact that it is visible in all filter sets). Equivalent results were observed in frozen sec- tions. Essentially no staining was observed in control brain, which had been shown to contain no plaques or NFTs by the standard CERAD neuropathology protocol (Mirra et al., 1991) (data not shown).
The tissue staining results supported the specificity of BTA-1 for ␤-sheet deposits in a qualitative manner, but the 100 nM BTA-1 concentration used for staining was not representative of the low or subnanomolar concentrations achieved by typical PET ligands in vivo. In addition, it is possible that the fluorescence properties of BTA-1 change after binding to amyloid in a way that enhances the fluorescence similar to that observed for thioflavin-T (LeVine, 1993) . This could make the staining appear more specific than it actually was. Therefore, quantitative binding studies were performed in tissue homogenates using 1. 3 H]BTA-1 was bound to amyloid-containing AD brain than to the control or NAD brains, which lacked observable amyloid deposits ( p Ͻ 0.0002) (Fig. 3) . Using 1.2 nM [ 3 H]BTA-1, the average amount of [ 3 H]BTA-1 bound to AD frontal gray (0.73 Ϯ 0.21 pmol/mg wet weight) was Ͼ10-fold higher than that bound to frontal gray obtained from either control brain (0.061 Ϯ 0.023 pmol/mg wet weight) or NAD brain (0.072 Ϯ 0.021 pmol/mg wet weight).
As expected, and confirming the specificity of BTA-1, a very different finding was observed in the cerebellum where fibrillar (i.e., Congo red or thioflavin-S positive) amyloid deposits are very rarely observed (Joachim et al., 1989; Yamaguchi et al., 1989; Mann et al., 1996) (Fig. 3A) . Binding was low in the cerebellar homogenates of all three groups, and there was complete overlap between binding to AD cerebellum and binding to cerebellum from control and NAD brains.
The lack of difference in [ 3 H]BTA-1 binding in cerebellum is important because it identifies this brain area as a potential reference tissue that could be used to simplify the quantitation of future PET studies. To more precisely examine this issue, ratios of [ 3 H]BTA-1 binding to frontal gray and cerebellum were determined for each individual brain studied, and the data were expressed as the frontal/cerebellar ratio for each brain (Fig. 3B ).
When expressed in this manner, the clear differentiation between amyloid-containing AD brain and the nonamyloid-containing control groups remained. The ratio in AD brain (7.8 Ϯ 4.0) was Ͼ10-fold higher than the ratio calculated in either control brain Control brains showed only low-affinity binding, having a mean K d of 132 Ϯ 59 nM and a mean B max of 11.3 Ϯ 5.2 pmol/mg wet weight (Fig. 4) . The frontal gray matter samples used in this study were dissected to remove the underlying white matter as much as possible. Comparing the frontal gray matter from an AD brain with the white matter immediately underlying it showed a marked difference in high-affinity Figure 4 . In contrast to the frontal gray matter, the frontal white matter showed only a low-affinity binding component, similar to that seen in control brain frontal gray. This low-affinity binding component in control frontal gray and AD frontal white matter would not play a significant role in in vivo imaging studies using high specific-activity radiotracers present at low nanomolar concentrations.
To (Fig. 5A) , similar in numbers to those found in many AD cases (Fig. 5B) ; however, it had no neuritic or diffuse plaques in any area of the brain (Fig. 5 A, C,E) . (Table 2) . A similar survey of these same brain areas in a Braak VI AD brain (Table 2) showed low binding in NFT-free cerebellum and NFT-rich EC and Ͼ10-fold higher levels in frontal gray, where there are frequent numbers of neuritic plaques (Fig. 5D) . The extensive NFT pathology in the EC of the Cntl 04 and AD 01 brains, coupled with the low [ NP, Neuritic plaques; PMI, postmortem interval; AD, Alzheimer's disease; AA, amyloid angiopathy; DLB, dementia with Lewy Bodies; SD, standard deviation; p ϭ (vs AD), p values compared with corresponding values for AD cases; Cntl, control; NAD, demented, non-Alzheimer's disease; MND, motor neuron disease-inclusion dementia (Jackson et al., 1996) ; DLDHF, dementia lacking distinctive histologic features (Mann, 1998) ; neuropath; Dx, neuropathological diagnosis. a CERAD criteria (Mirra et al., 1991) . b Scored according to consensus criteria (McKeith et al., 1996) .
frontal gray. The AD 01 brain showed diffuse amyloid plaque deposits in the EC (Fig. 5B) , which also did not appear to produce significant [ 3 H]BTA-1 binding. The frontal cortex had extensive amyloid plaques that were both compact and diffuse and associated with high levels of [ 3 H]BTA-1 binding (Fig. 5D , Table 2 ). The qualitative BTA-1 staining of NFTs, seen at 100 nM concentrations (Fig. 2) , is apparently not reflected by significant amounts of [ (Fig. 6) . In fact, the correlation between K i values determined in AD brain and synthetic A␤ binding assays (r ϭ 0.88) was no worse than the correlation of K i values determined with two separately aggregated lots of synthetic A␤(1-40) (r ϭ 0.89) (Fig. 6 ). This finding suggested that the [ 3 H]BTA-1 binding site in AD brain homogenates had the same structure-affinity relationship as the binding site in suspensions of pure, synthetic A␤(1-40) fibrils and was consistent with the hypothesis that [
3 H]BTA-1 binding to AD brain homogenates was dominated by binding to fibrillar A␤ deposits.
Additional experiments were performed using the resources of the NIMH Psychoactive Drug Screening Program to assess whether BTA-1 interacts with any of a representative array of neurotransmitter receptors and transporters (Rothman et al., 2000; Roth et al., 2001) . The array has been published previously (Roth et al., 2001 ) and includes adrenergic, serotonergic, muscarininc, dopaminergic, opiate, vasopressin, oxytocin, GABA, glutamate, and imidazoline receptor sites. Using 10 M BTA-1, no inhibition was observed at any receptor site except at the norepinephrine transporter, where the K i of BTA-1 was 4504 Ϯ 31 nM, a value 1000-fold higher than the K d for A␤(1-40) or AD brain.
Discussion
Although a previous study showed good pharmacokinetic properties for BTA-1 in normal mice (Mathis et al., 2002) , it remained to be shown that BTA-1 could specifically bind to its amyloid target in human brain and to more precisely characterize that target in the complex milieu of human AD brain. The ability of BTA-1 to fluorescently stain amyloid deposits in postmortem tissue sections gives some indication that this compound would specifically bind amyloid deposits. However, this staining is a qualitative technique and certainly does not prove sufficient specificity for use as an in vivo PET amyloid-imaging agent in humans. In an effort to address this question, we quantitatively examined the binding of [
3 H]BTA-1 to homogenates of post- (Styren et al., 2000) . Marked atrophy of AD tissue was notable in all regions. In the entorhinal cortex of the control subject ( A), frequent numbers of NFTs were seen, whereas there were no amyloid deposits. In the AD case ( B), there also were frequent NFTs along with diffuse amyloid deposits (arrows). X-34-positive NFTs and amyloid plaques were absent from the frontal cortex of the control case ( C), whereas they were abundant in AD ( D). There was no detectable X-34 staining of plaques or NFT in control ( E) and AD ( F) cerebellum. Control frontal cortex ( C) and cerebellum from both control and AD (E, F ) show small stellate cells that stain with X-34. Scale bar, 200 m. ]BTA-1 to establish a diagnosis. The validation of BTA-1, or any other compound, as an accurate tool to quantify amyloid is a complex process composed of many steps such as the one described in this study. In addition, it should be recognized that the frontal cortex does not represent the area of maximal pathologic change for several of the diseases included in the NAD group, and one would need to examine other brain areas to adequately address diagnostic issues in these cases.
The purpose of this study was solely to determine whether the binding of [ 3 H]BTA-1 to areas of human brain with abundant amyloid deposits (e.g., AD frontal gray) was dominated by a specific interaction with the amyloid deposits. It was possible that [ 3 H]BTA-1 could have nonspecific interactions with binding sites on non-amyloid components in brain that would be of sufficient magnitude to mask the specific, amyloid binding observed in AD brain. Therefore, both control groups were chosen for the absence of visible A␤ deposits to assess the contribution of the non-amyloid components in isolation. The NAD group was included to control for the possibility that [
3 H]BTA-1 binding was affected by general neurodegenerative processes in a manner unrelated to amyloid deposition. Likewise, it is possible that highly lipophilic brain areas such as white matter from both AD and control brains could have large amounts of nonspecific, lipophilic interactions with [
3 H]BTA-1 that would overshadow the specific, amyloid binding in the overlying cortex. Our results indicated that high-affinity [
3 H]BTA-1 binding was much greater in AD frontal gray than either control frontal gray or AD frontal white matter and suggested that the binding of [ 3 H]BTA-1 to AD brain mainly represented a specific interaction with A␤ deposits.
Taken together with the previously reported pharmacokinetic properties of [
11 C]BTA-1 in mice and successful in vivo imaging of plaques in transgenic mice using BTA-1 and multiphoton microscopy (Mathis et al., 2002) , the findings of the present study suggest that BTA-1 is a good candidate as an in vivo PET amyloidimaging agent. Further, detailed, quantitative validation studies in transgenic mice will need to be performed to confirm the potential of BTA-1. In addition, pharmacokinetic studies are underway in primate brain to verify the mouse studies. Promising results from all of these studies and an acceptable toxicological profile will justify preliminary studies in human subjects with and without AD.
